The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.0 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Lectures Included

• Triglyceride as a Factor in Residual CVD Risk - Eliot A. Brinton, MD
• Disease State Network Year-in-Review: Lipids and CV Health - Vishnu Priya Pulipati, MD; Eliot A. Brinton, MD; Betul Hatipoglu, MD
• Cardiometabolic Effects of Fatty Kidney Disease - Christian W. Mende, MD
• Cardiovascular Disease and Diabetes: Assessing Risks and Prioritizing Therapies - Peter Reaven, MD
• Nonalcoholic Fatty Liver Guideline - Scott Isaacs, MD, FACP, FACE; Romina Lomonaco, MD; Kenneth Cusi, MD, FACP, FACE
• The New Biology of Pheochromocytomas - Karel Pacak, MD, PhD, DSc, FACE

Learning Objectives

Upon completion of the activity, participants should be able to:

• Discuss the prevalence and importance of mild to moderate elevations of fasting triglycerides (TG) as a risk factor for atherosclerotic cardiovascular disease (ASCVD) and implement appropriate criteria for use of prescription icosapent ethyl (IPE) in ASCVD prevention
• Evaluate the recent advances in lipids and cardiovascular risk factors during 2021-2022
• Recognize factors of Fatty Kidney Disease and address imaging and therapies for treatment
• Discuss the role of glucose control on cardiovascular outcomes in type 2 diabetes and identify the glucose lowering medications most effective in reducing cardiovascular risk
• Outline the newest clinical and basic discoveries related to hereditary pheochromocytoma and paraganglioma as well as newest imaging guidelines and treatment options

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

• Eliot A Brinton, MD, FACE, FAHA, FNLA - President Utah Lipid Center: 89bio (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- January 1, 2021); Amarin (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Support (Status: Ongoing); Amgen (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Amryt (Self) : Honorarium (Status: Ongoing); Dalcor (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Esperion (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- August 1, 2021), Honorarium (Status: Terminated --- August 1, 2021); Genzyme () : Speaker's Bureau; Kowa (Self) : Grant/Research Support (Status: Ongoing); Merck () : Consultant, Speaker's Bureau; Novartis (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Pfizer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
  
• Christian W Mende, MD - Clinical Professor of Medicine UCSD: Bayer, AstraZeneca, Lilly, Boehringer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing)
  
• Peter Reaven, MD - Professor of Clinical Medicine University of Arizona, Phoenix: AstraZeneca (Self) : Research Grant (Status: Terminated --- july 2021); Dexcom (Self) : Research Grant (Status: Ongoing)
  
• Cecilia C Low Wang, MD - Professor of Medicine University of Colorado Anschutz Medical Campus School of Medicine: Dexcom Inc (Self) : Research Grant (Status: Ongoing).
  
• Oksana Hamidi, DO - Endocrinologist UT Southwestern Medical Center: Corcept Therapeutics Inc (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- March 2020); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- October 2020); Stongbridge Pharma (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- Nov 2020)

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

• Eliot A. Brinton, MD, FACE, FAHA, FNLA
• Vishnu Priya Pulipati, MD
• Betul Hatipoglu, MD
• Christian W. Mende, MD
• Peter Reaven, MD
• Scott Isaacs, MD, FACP, FACE
• Romina Lomonaco, MD
• Kenneth Cusi, MD, FACP, FACE